Scott L. Wexelblatt, MD
- Regional Director of Newborn Services, Perinatal Institute
- Associate Professor, UC Department of Pediatrics
- scott.wexelblatt@cchmc.org
- Board Certified
About
Biography
Working in medicine — particularly pediatrics — has long been my dream. At a young age, I was inspired by my own pediatrician, Dr. Marshall “Buzz” Land, who would later become my mentor at the University of Vermont College of Medicine.
Throughout my career, I’ve noticed a need for standardizing and improving care. This insufficiency drew me to research. I have a particular interest in neonatal opioid withdrawal syndrome.
The overall goals of my work are to reduce length of stay, lower the percentage of infants requiring medications and reduce days of opioid treatment.
I was a faculty member and part of the Neonatal Abstinence Syndrome project with the Ohio Perinatal Quality Collaborative (OPQC), which focuses on reducing preterm births and improving newborn and maternal outcomes.
MD: University of Vermont College of Medicine, Burlington, VT, 1996.
Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Certification: American Board of Pediatrics, 1999.
Interests
Neonatal Abstinence Syndrome
Services and Specialties
Neonatology, Perinatal
Research Areas
Neonatology
Publications
Rates of substance and polysubstance use through universal maternal testing at the time of delivery. Journal of Perinatology. 2022; 42:1026-1031.
A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome. Pharmacology and Therapeutics. 2022; 234.
Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome. Clinical Pharmacology and Therapeutics. 2022; 111:496-508.
Regional comparison of self-reported late pregnancy cigarette smoking to mass spectrometry analysis. Journal of Perinatology. 2021; 41:2417-2423.
Quality Improvement Initiative to Improve Healthcare Providers' Attitudes towards Mothers with Opioid Use Disorder. Pediatric Quality and Safety. 2021; 6.
Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. Clinical Pharmacokinetics. 2021; 60:249-259.
Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics. Expert Opinion on Drug Metabolism and Toxicology. 2021; 17:87-103.
Orchestrated Testing of Formula Type to Reduce Length of Stay in Neonatal Abstinence Syndrome. Pediatrics. 2020; 146.
Subclinical and Overt Newborn Opioid Exposure: Prevalence and First-Year Healthcare Utilization. Journal of Pediatrics. 2020; 222:52-58.e1.
Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. Controlled Clinical Trials. 2020; 93.
From the Blog
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2022 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey